RLS Global AB (publ) (RLS.ST)
RLS Global AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mölndal, SE. The stock last traded at $0.45, down 0.89% on the session, giving a market capitalisation of $35.7M. Its beta of 0.57 implies it has historically moved less than the broad market.
RLS Global AB (publ) is a Swedish medical technology firm that specializes in developing and commercializing therapeutic products for conditions within wound and oral care. Among its key offerings are ChloraSolv, a treatment specifically designed for chronic diabetic foot and leg ulcers in diabetic patients, and CariSolv, a unique gel employed for the removal of dental caries. Established in 1996, the company maintains its headquarters in Mölndal, Sweden.
RLS Global AB (publ) is most often compared with the following Healthcare names: